PET study shows promising results for antipsychotic drug

12/21/2009 | PR Newswire

A Phase I PET study showed Intra-Cellular Therapies' experimental antipsychotic drug ITI-007 interacted with key targets in the living human brain, a mechanism that will influence drug action. "We believe that these results will translate into a reduced need to impose high doses of drugs on patients suffering from schizophrenia and other disorders," CEO Sharon Mates said.

View Full Article in:

PR Newswire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC